Verve Therapeutics

CAMBRIDGE, MA · Founded 2018 · CIK 0001840574 · Biotech · Acquired

Base editing therapeutics that permanently reduce LDL cholesterol by targeting PCSK9 gene

vervetx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$94M
1 Form D · Jan 2021
69 months since last filing
Contracts
—
No federal contracts on record
Patents
40
9 granted · 31 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$93,999,993
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2836Arcutis Biotherapeutics, Inc.—$94M
2837OMNI BIO PHARMACEUTICAL, INC.—$28M
2838ReAlta Life Sciences, Inc.—$94M
2839Verve Therapeutics—$94M
2840Scorpion Therapeutics—$297M
2841VASCULAR BIOSCIENCES, INC.——
2842EXPRESSION THERAPEUTICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Burt AdelmanDirector
  • Andrew AsheExecutive Officer
  • Andrew BellingerExecutive Officer
  • John EvansDirector
  • Sekar KathiresanDirector · Executive Officer
  • Anthony PhilippakisDirector
  • Krishna YeshwantDirector

Patents

USPTO · 9 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.